Ensysce Biosciences (ENSCW) Total Non-Current Liabilities (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Total Non-Current Liabilities of $35.0 for Q3 2025, down 98.91% year-over-year from $3213.0 in Q3 2024, and down 96.61% quarter-over-quarter from $1033.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Total Non-Current Liabilities data on file, last reported at $35.0 in Q3 2025.
- Total Non-Current Liabilities for Q3 2025 came in at $35.0, down 98.91% year-over-year; the trailing twelve-month figure through Sep 2025 was $35.0 (down 98.91% YoY), and the FY2024 annual result was $10096.0, down 61.74% from the prior year.
- Total Non-Current Liabilities eased to $35.0 in Q3 2025 per ENSCW's latest filing, from $1033.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.4 million in Q2 2022 and troughed at $35.0 in Q3 2025.
- A 5-year average of $1.6 million and a median of $69507.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities jumped 978.83% in 2021, then plunged 99.43% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $8.1 million in 2021, then sank by 94.43% to $450494.0 in 2022, then slumped by 94.14% to $26388.0 in 2023, then sank by 61.74% to $10096.0 in 2024, then plunged by 99.65% to $35.0 in 2025.
- Business Quant data shows ENSCW's Total Non-Current Liabilities at $35.0 in Q3 2025, $1033.0 in Q2 2025, and $130180.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 35.00 |
| Jun 30, 2025 | 1,033.00 |
| Mar 31, 2025 | 130,180.00 |
| Dec 31, 2024 | 10,096.00 |
| Sep 30, 2024 | 3,213.00 |
| Jun 30, 2024 | 9,615.00 |
| Mar 31, 2024 | 17,433.00 |
| Dec 31, 2023 | 26,388.00 |
| Sep 30, 2023 | 30,473.00 |
| Jun 30, 2023 | 47,696.00 |
| Mar 31, 2023 | 91,318.00 |
| Dec 31, 2022 | 450,494.00 |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 8.39 Mn |
| Mar 31, 2022 | 2.46 Mn |
| Dec 31, 2021 | 8.09 Mn |
| Sep 30, 2021 | 3.07 Mn |
| Mar 31, 2021 | 2.78 Mn |
| Dec 31, 2020 | 750,234.00 |
| Dec 31, 2019 | 10.34 Mn |